9-Oxo-9-(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)nonanoic acid

ID: ALA4793848

PubChem CID: 71523643

Max Phase: Preclinical

Molecular Formula: C20H27F3N2O3

Molecular Weight: 400.44

Molecule Type: Unknown

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C(O)CCCCCCCC(=O)N1CCN(c2ccc(C(F)(F)F)cc2)CC1

Standard InChI:  InChI=1S/C20H27F3N2O3/c21-20(22,23)16-8-10-17(11-9-16)24-12-14-25(15-13-24)18(26)6-4-2-1-3-5-7-19(27)28/h8-11H,1-7,12-15H2,(H,27,28)

Standard InChI Key:  IRQWPZTVZZRGMK-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 28 29  0  0  0  0  0  0  0  0999 V2000
   24.5735   -3.0005    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   24.5776   -2.1792    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.8637   -2.5883    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   27.8629   -2.1833    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   28.2674   -2.8932    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.0805   -2.8958    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.4952   -2.1901    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   29.0866   -1.4803    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.2674   -1.4760    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.0446   -2.1850    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.6330   -1.4712    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.8125   -1.4702    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.4025   -2.1823    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.8149   -2.8968    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.6341   -2.8943    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.1681   -1.4711    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   30.3124   -2.1939    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.7178   -2.9034    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.7242   -1.4880    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   31.5349   -2.9071    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.9403   -3.6167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.7575   -3.6204    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.1629   -4.3300    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.9800   -4.3337    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.3854   -5.0432    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.2026   -5.0469    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.6080   -5.7565    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   35.6144   -4.3411    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  0
  3  2  1  0
  4  5  1  0
  4  9  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 10  1  0
  4 10  1  0
 13  2  1  0
  2 16  1  0
  7 17  1  0
 17 18  1  0
 17 19  2  0
 18 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  1  0
 25 26  1  0
 26 27  1  0
 26 28  2  0
M  END

Associated Targets(non-human)

C2C12 (756 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 400.44Molecular Weight (Monoisotopic): 400.1974AlogP: 4.17#Rotatable Bonds: 9
Polar Surface Area: 60.85Molecular Species: ACIDHBA: 3HBD: 1
#RO5 Violations: HBA (Lipinski): 5HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 4.57CX Basic pKa: 2.85CX LogP: 3.95CX LogD: 1.32
Aromatic Rings: 1Heavy Atoms: 28QED Weighted: 0.63Np Likeness Score: -0.98

References

1. Devine R,Kelada M,Leonard S,Martin DSD,Walsh JMD,Breen CJ,Driver RB,Kinsella GK,Findlay JBC,Stephens JC.  (2020)  Design, synthesis, and biological evaluation of aryl piperazines with potential as antidiabetic agents via the stimulation of glucose uptake and inhibition of NADH:ubiquinone oxidoreductase.,  202  [PMID:32645646] [10.1016/j.ejmech.2020.112416]

Source